Silo Pharma SPC-15 US Patent Allowance
Analysis based on 7 articles · First reported Sep 18, 2026 · Last updated Sep 18, 2026
The allowance strengthens Silo Pharma's intellectual property position around its lead PTSD candidate, a modest positive for a micro-cap developmental biopharmaceutical name with no approved products. Market impact is limited given the early-stage nature of SPC-15 and the small market capitalization, so the news is unlikely to move broader biotech or equity markets.
Silo Pharma announced that the United States — United States Patent and Trademark Office issued a Notice of Allowance for a patent application covering its lead asset SPC-15, an investigational intranasal therapeutic being developed for post-traumatic stress disorder. The application, titled Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior, covers both composition and method claims for preventing or delaying behavioral responses associated with stress. A Notice of Allowance means the USPTO has completed its examination and determined the application meets patentability requirements, with the patent expected to be granted shortly. The same invention is already covered by a corresponding patent issued by the International — European Patent Office earlier in 2026. CEO Eric Weisblum said securing US patent protection is an important component of the company strategy for SPC-15 as it advances the drug development for PTSD. Silo Pharma is a developmental-stage biopharmaceutical company whose portfolio also includes SP-26 for fibromyalgia and chronic pain, a preclinical Alzheimer's asset, and the wholly owned AI subsidiary QwikAgents. The company holds numerous issued and allowed patents. The stock closed the prior session at 1.72 dollars, down 2.27 percent, and traded lower in pre-market.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard